Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT01327846
Other study ID # CACZ885M2301
Secondary ID 2010-022970-14
Status Completed
Phase Phase 3
First received
Last updated
Start date April 11, 2011
Est. completion date April 14, 2019

Study information

Verified date January 2020
Source Novartis
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Main Study (CACZ885M2301): The purpose of the pivotal phase of this trial was to test the hypothesis that canakinumab treatment of patients with myocardial infarction (MI) at least one month prior to study entry and elevated hsCRP could prevent recurrent cardiovascular events.

The purpose of the extension phase of the main study is to collect additional long-term safety data on continued exposure to canakinumab in patients who participated in the pivotal phase.

Sub-study 1 (CACZ885M2301S1): The purpose of this sub-study was to evaluate the effect of quarterly subcutaneous canakinumab treatment for 24 months comparted with placebo on the carotid plaque burden measured by integrated vascular MRI in patients enrolled in the CACZ885M2301 study (CANTOS).

Sub-study 2 (CACZ885M2301S2): The purpose of this CANTOS sub-study was to determine whether, in patients with type 2 diabetes participating in the CANTOS main study, canakinumab compared to placebo, on top of standard of care could increase insulin secretion and insulin sensitivity.


Description:

Sub-study 1 and 2 were terminated prior to data collection from subjects. However, there is an ongoing extension trial where patients are receiving open-drug label.


Recruitment information / eligibility

Status Completed
Enrollment 10066
Est. completion date April 14, 2019
Est. primary completion date March 28, 2017
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Main Study Inclusion Criteria:

- Written informed consent

- Male, or Female of non-child-bearing potential

- Age = 18 years.

- Spontaneous MI at least 30 days before randomization. hsCRP = 2 mg/L

Substudy 1 Inclusion:

- All Inclusion from Main Study

- Acquisition of evaluable baseline MRI images of bilateral carotid arteries by the imaging core laboratory

Substudy 2 Inclusion:

- All inclusion from Main Study

- T2D at baseline per Main protocol criteria and be on a stable anti-hyperglycemic medication for at least 4 weeks prior to the baseline OGTT test

- Willing to have the OGTT assessment started before 10 am

Main Study Exclusion Criteria:

- Pregnant or nursing (lactating) women

- Women of child-bearing potential

- Any of the following concomitant diseases

- Planned coronary revascularization (PCI or CABG)

- Major non-cardiac surgical or endoscopic procedure within past 6 months

- Multi-vessel CABG surgery within the past 3 years

- Symptomatic patients with Class IV heart failure (HF) (New York Heart Association [NYHA].

- Uncontrolled hypertension

- Uncontrolled diabetes

- History or evidence of active tuberculosis (TB) infection Substudy 1 Exclusion

- All Main exclusion

- Patients with prior history of carotid angioplasty, stenting, or carotid atherectomy

- Patients with contraindications to MRI examination (brain aneurysm clip, implanted neural stimulator, implanted cardiac pacemaker, pacemaker wires or defibrillator, prosthetic heart valves, cochlear implant, ocular foreign body or other implanted body, tattoos, implanted insulin pump, metal shrapnel or bullet)

- Patients prone to claustrophobia or known anxiety disorders

- BMI > 40 kg/m2 Substudy 2 Exclusion

- This sub-study does not have any additional exclusion criteria.

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Canakinumab

Placebo

Standard of care
Standard of care post-MI background therapy includes, but is not limited to, lipid lowering, anti-hypertensive, beta blockers, and anti-platelet therapy as appropriate

Locations

Country Name City State
Argentina Novartis Investigative Site Bahía Blanca Buenos Aires
Argentina Novartis Investigative Site Caba Buenos Aires
Argentina Novartis Investigative Site Caba Buenos Aires
Argentina Novartis Investigative Site Caba Buenos Aires
Argentina Novartis Investigative Site Caba Buenos Aires
Argentina Novartis Investigative Site Caba Buenos Aires
Argentina Novartis Investigative Site Caba Buenos Aires
Argentina Novartis Investigative Site Caba
Argentina Novartis Investigative Site Caba Capital Federal
Argentina Novartis Investigative Site Caba Capital Federal
Argentina Novartis Investigative Site Cipolletti Rio Negro
Argentina Novartis Investigative Site Cordoba
Argentina Novartis Investigative Site Cordoba
Argentina Novartis Investigative Site Cordoba
Argentina Novartis Investigative Site Cordoba
Argentina Novartis Investigative Site Cordoba
Argentina Novartis Investigative Site Cordoba
Argentina Novartis Investigative Site Cordoba
Argentina Novartis Investigative Site Cordoba
Argentina Novartis Investigative Site Cordoba
Argentina Novartis Investigative Site Cordoba
Argentina Novartis Investigative Site Cordoba
Argentina Novartis Investigative Site Cordoba
Argentina Novartis Investigative Site Corrientes
Argentina Novartis Investigative Site Corrientes
Argentina Novartis Investigative Site Corrientes
Argentina Novartis Investigative Site Corrientes
Argentina Novartis Investigative Site Formosa
Argentina Novartis Investigative Site Formosa
Argentina Novartis Investigative Site Mar del Plata Buenos Aires
Argentina Novartis Investigative Site Mar del Plata Buenos Aires
Argentina Novartis Investigative Site Posadas Misiones
Argentina Novartis Investigative Site Quilmes Buenos Aires
Argentina Novartis Investigative Site Quilmes Buenos Aires
Argentina Novartis Investigative Site Ramos Mejia Buenos Aires
Argentina Novartis Investigative Site Rosario Santa Fe
Argentina Novartis Investigative Site Rosario Santa Fe
Argentina Novartis Investigative Site Rosario Santa Fe
Argentina Novartis Investigative Site Salta
Argentina Novartis Investigative Site San Isidro Buenos Aires
Argentina Novartis Investigative Site San Luis
Argentina Novartis Investigative Site San Miguel de Tucuman Tucuman
Argentina Novartis Investigative Site San Miguel de Tucuman Tucuman
Argentina Novartis Investigative Site San Miguel de Tucuman Tucuman
Argentina Novartis Investigative Site San Nicolas Buenos Aires
Argentina Novartis Investigative Site San Salvador de Jujuy Jujuy
Argentina Novartis Investigative Site Santa Fe
Argentina Novartis Investigative Site Santa Fe
Argentina Novartis Investigative Site Santa Fe
Argentina Novartis Investigative Site Santiago del Estero
Argentina Novartis Investigative Site Tucuman
Argentina Novartis Investigative Site Tucuman San Miguel De Tucuman
Argentina Novartis Investigative Site Zarate Buenos Aires
Australia Novartis Investigative Site Bateman Western Australia
Australia Novartis Investigative Site Bundoora Victoria
Australia Novartis Investigative Site Garran Australian Capital Territory
Australia Novartis Investigative Site Geelong Victoria
Australia Novartis Investigative Site Gosford New South Wales
Australia Novartis Investigative Site Hobart Tasmania
Australia Novartis Investigative Site Joondalup Western Australia
Australia Novartis Investigative Site Kogarah New South Wales
Australia Novartis Investigative Site Liverpool New South Wales
Australia Novartis Investigative Site Milton Queensland
Australia Novartis Investigative Site Perth Western Australia
Australia Novartis Investigative Site Southport Queensland
Austria Novartis Investigative Site Graz
Austria Novartis Investigative Site Linz
Austria Novartis Investigative Site Linz
Austria Novartis Investigative Site Saint Stefan
Austria Novartis Investigative Site Salzburg
Austria Novartis Investigative Site Vienna
Austria Novartis Investigative Site Wien
Belgium Novartis Investigative Site Aalst
Belgium Novartis Investigative Site Bonheiden
Belgium Novartis Investigative Site Brasschaat
Belgium Novartis Investigative Site Brussel
Belgium Novartis Investigative Site De Pinte
Belgium Novartis Investigative Site Genk
Belgium Novartis Investigative Site Gent
Belgium Novartis Investigative Site Hasselt
Belgium Novartis Investigative Site Huy
Belgium Novartis Investigative Site Leuven
Belgium Novartis Investigative Site Mechelen
Belgium Novartis Investigative Site Ottignies
Belgium Novartis Investigative Site Tienen
Brazil Novartis Investigative Site Belem PA
Brazil Novartis Investigative Site Belo Horizonte MG
Brazil Novartis Investigative Site Belo Horizonte MG
Brazil Novartis Investigative Site Blumenau SC
Brazil Novartis Investigative Site Brasilia DF
Brazil Novartis Investigative Site Brasilia DF
Brazil Novartis Investigative Site Campinas SP
Brazil Novartis Investigative Site Campinas SP
Brazil Novartis Investigative Site Campinas SP
Brazil Novartis Investigative Site Campo Grande MS
Brazil Novartis Investigative Site Curitiba PR
Brazil Novartis Investigative Site Fortaleza CE
Brazil Novartis Investigative Site Goiania GO
Brazil Novartis Investigative Site Goiania GO
Brazil Novartis Investigative Site Passo Fundo RS
Brazil Novartis Investigative Site Pelotas RS
Brazil Novartis Investigative Site Porto Alegre RS
Brazil Novartis Investigative Site Porto Alegre RS
Brazil Novartis Investigative Site Porto Alegre RS
Brazil Novartis Investigative Site Porto Alegre RS
Brazil Novartis Investigative Site Porto Alegre Rio Grande Do Sul
Brazil Novartis Investigative Site Recife PE
Brazil Novartis Investigative Site Salvador BA
Brazil Novartis Investigative Site Salvador BA
Brazil Novartis Investigative Site Santo Andre SP
Brazil Novartis Investigative Site Sao Jose do Rio Preto SP
Brazil Novartis Investigative Site Sao Paulo SP
Brazil Novartis Investigative Site Sao Paulo SP
Brazil Novartis Investigative Site Sao Paulo SP
Brazil Novartis Investigative Site São Paulo SP
Brazil Novartis Investigative Site Tatuí SP
Brazil Novartis Investigative Site Uberlandia MG
Brazil Novartis Investigative Site Uberlandia Minas Gerais
Brazil Novartis Investigative Site Votuporanga SP
Bulgaria Novartis Investigative Site Pazardzhik
Bulgaria Novartis Investigative Site Pleven
Bulgaria Novartis Investigative Site Plovdiv
Bulgaria Novartis Investigative Site Sofia
Bulgaria Novartis Investigative Site Sofia
Bulgaria Novartis Investigative Site Sofia
Bulgaria Novartis Investigative Site Sofia
Bulgaria Novartis Investigative Site Sofia
Bulgaria Novartis Investigative Site Sofia
Bulgaria Novartis Investigative Site Sofia
Canada Novartis Investigative Site Cambridge Ontario
Canada Novartis Investigative Site Drummondville Quebec
Canada Novartis Investigative Site Etobicoke Ontario
Canada Novartis Investigative Site Gatineau Quebec
Canada Novartis Investigative Site Granby Quebec
Canada Novartis Investigative Site Halifax Nova Scotia
Canada Novartis Investigative Site Hamilton Ontario
Canada Novartis Investigative Site Joliette Quebec
Canada Novartis Investigative Site Kitchener Ontario
Canada Novartis Investigative Site Lachine Quebec
Canada Novartis Investigative Site Laval Quebec
Canada Novartis Investigative Site Levis Quebec
Canada Novartis Investigative Site Longueuil Quebec
Canada Novartis Investigative Site Mississauga Ontario
Canada Novartis Investigative Site Montreal Quebec
Canada Novartis Investigative Site Montreal Quebec
Canada Novartis Investigative Site Mount Pearl Newfoundland and Labrador
Canada Novartis Investigative Site New Westminster British Columbia
Canada Novartis Investigative Site Newmarket Ontario
Canada Novartis Investigative Site Newmarket Ontario
Canada Novartis Investigative Site Ottawa Ontario
Canada Novartis Investigative Site Peterborough Ontario
Canada Novartis Investigative Site Quebec
Canada Novartis Investigative Site Quebec
Canada Novartis Investigative Site Quebec
Canada Novartis Investigative Site Sainte Foy Quebec
Canada Novartis Investigative Site Saskatoon Saskatchewan
Canada Novartis Investigative Site Scarborough Ontario
Canada Novartis Investigative Site Sherbrooke Quebec
Canada Novartis Investigative Site St-Jean-sur-Richelieu Quebec
Canada Novartis Investigative Site Ste-Foy Quebec
Canada Novartis Investigative Site Surrey British Columbia
Canada Novartis Investigative Site Terrebonne Quebec
Canada Novartis Investigative Site Thetford Mines Quebec
Canada Novartis Investigative Site Toronto Ontario
Canada Novartis Investigative Site Toronto Ontario
Canada Novartis Investigative Site Victoria British Columbia
Canada Novartis Investigative Site Winnipeg Manitoba
China Novartis Investigative Site Baotou Inner Mongolia
China Novartis Investigative Site Beijing
China Novartis Investigative Site Beijing
China Novartis Investigative Site Beijing
China Novartis Investigative Site Beijing
China Novartis Investigative Site Beijing
China Novartis Investigative Site Beijing
China Novartis Investigative Site Beijing Beijing
China Novartis Investigative Site Changchun Jilin
China Novartis Investigative Site Changsha Hunan
China Novartis Investigative Site Chongqing Chongqing
China Novartis Investigative Site Fuzhou Fujian
China Novartis Investigative Site Guang Zhou Guangdong
China Novartis Investigative Site Guangzhou Guangdong
China Novartis Investigative Site Hangzhou Zhejiang
China Novartis Investigative Site Hangzhou Zhejiang
China Novartis Investigative Site Harbin Heilongjiang
China Novartis Investigative Site Nanjing Jiangsu
China Novartis Investigative Site Nanning Guangxi
China Novartis Investigative Site Shanghai Shanghai
China Novartis Investigative Site Shanghai Shanghai
China Novartis Investigative Site Shanghai
China Novartis Investigative Site Shanghai City Shanghai
China Novartis Investigative Site Shenyang Liaoning
China Novartis Investigative Site Shenyang Liaoning
China Novartis Investigative Site Shijiazhuang Hebei
China Novartis Investigative Site Suzhou Jiangsu
China Novartis Investigative Site Tianjin Tianjin
China Novartis Investigative Site Tianjin
China Novartis Investigative Site Tianjin
China Novartis Investigative Site Wuhan Hubei
China Novartis Investigative Site Wuhan Hubei
China Novartis Investigative Site Xian Shanxi
China Novartis Investigative Site Xian Shanxi
Colombia Novartis Investigative Site Armenia
Colombia Novartis Investigative Site Baranquilla
Colombia Novartis Investigative Site Baranquilla Atlantico
Colombia Novartis Investigative Site Barranquilla Atlantico
Colombia Novartis Investigative Site Barranquilla
Colombia Novartis Investigative Site Barranquilla
Colombia Novartis Investigative Site Bogota
Colombia Novartis Investigative Site Bogotá
Colombia Novartis Investigative Site Bucaramanga Santander
Colombia Novartis Investigative Site Cali
Colombia Novartis Investigative Site Cartagena Bolivar
Colombia Novartis Investigative Site Cartegena
Colombia Novartis Investigative Site Florida Blanca
Colombia Novartis Investigative Site Floridablanca Santander
Colombia Novartis Investigative Site Manizales Caldas
Croatia Novartis Investigative Site Cakovec
Croatia Novartis Investigative Site Koprivnica
Croatia Novartis Investigative Site Krapinske toplice
Croatia Novartis Investigative Site Krapinske Toplice
Croatia Novartis Investigative Site Opatija
Croatia Novartis Investigative Site Rijeka
Croatia Novartis Investigative Site Varazdin HRV
Croatia Novartis Investigative Site Virovitica
Croatia Novartis Investigative Site Zagreb
Czechia Novartis Investigative Site Benesov
Czechia Novartis Investigative Site Brandys nad Labem Czech Republic
Czechia Novartis Investigative Site Brno Bohunice
Czechia Novartis Investigative Site Broumov
Czechia Novartis Investigative Site Jablonec nad Nisou Czech Republic
Czechia Novartis Investigative Site Kladno Czech Republic
Czechia Novartis Investigative Site Kolin
Czechia Novartis Investigative Site Liberec Czech Republic
Czechia Novartis Investigative Site Louny Czech Republic
Czechia Novartis Investigative Site Marianske lazne
Czechia Novartis Investigative Site Most CZE
Czechia Novartis Investigative Site Ostrava Czech Republic
Czechia Novartis Investigative Site Pardubice
Czechia Novartis Investigative Site Plzen Czech Republic
Czechia Novartis Investigative Site Prague 4 - Krc
Czechia Novartis Investigative Site Praha
Czechia Novartis Investigative Site Praha 11 Czech Republic
Czechia Novartis Investigative Site Praha 2 CZE
Czechia Novartis Investigative Site Praha 9 Czech Republic
Czechia Novartis Investigative Site Roznov pod Radhostem Czech Republic
Czechia Novartis Investigative Site Semily Czech Republic
Czechia Novartis Investigative Site Slany
Czechia Novartis Investigative Site Svitavy Czech Republic
Czechia Novartis Investigative Site Teplice
Czechia Novartis Investigative Site Trebic Czech Republic
Czechia Novartis Investigative Site Trutnov CZE
Czechia Novartis Investigative Site Uherske Hradiste
Czechia Novartis Investigative Site Usti nad Labem Czech Republic
Czechia Novartis Investigative Site Usti nad Orlici Czech Republic
Czechia Novartis Investigative Site Vyskov Czech Republic
Czechia Novartis Investigative Site Znojmo Czech Republic
Estonia Novartis Investigative Site Parnu
Estonia Novartis Investigative Site Saku
Estonia Novartis Investigative Site Tallinn
Estonia Novartis Investigative Site Tallinn
Estonia Novartis Investigative Site Tallinn
Estonia Novartis Investigative Site Tallinn
Estonia Novartis Investigative Site Tartu
Estonia Novartis Investigative Site Viljandi County
Estonia Novartis Investigative Site Võru
Germany Novartis Investigative Site Bad Krozingen
Germany Novartis Investigative Site Balve
Germany Novartis Investigative Site Berlin
Germany Novartis Investigative Site Berlin
Germany Novartis Investigative Site Berlin
Germany Novartis Investigative Site Berlin
Germany Novartis Investigative Site Berlin
Germany Novartis Investigative Site Berlin
Germany Novartis Investigative Site Berlin
Germany Novartis Investigative Site Bochum
Germany Novartis Investigative Site Borna
Germany Novartis Investigative Site Chemnitz
Germany Novartis Investigative Site Chemnitz
Germany Novartis Investigative Site Dillingen
Germany Novartis Investigative Site Dinslaken
Germany Novartis Investigative Site Dortmund
Germany Novartis Investigative Site Dresden
Germany Novartis Investigative Site Dresden
Germany Novartis Investigative Site Dresden
Germany Novartis Investigative Site Dresden
Germany Novartis Investigative Site Dresden
Germany Novartis Investigative Site Duisburg
Germany Novartis Investigative Site Düsseldorf
Germany Novartis Investigative Site Ebersbach
Germany Novartis Investigative Site Elsterwerda
Germany Novartis Investigative Site Erlangen
Germany Novartis Investigative Site Essen
Germany Novartis Investigative Site Essen
Germany Novartis Investigative Site Essen
Germany Novartis Investigative Site Falkensee
Germany Novartis Investigative Site Frankfurt
Germany Novartis Investigative Site Frankfurt
Germany Novartis Investigative Site Frankfurt am Main
Germany Novartis Investigative Site Freiburg
Germany Novartis Investigative Site Fulda
Germany Novartis Investigative Site Giengen
Germany Novartis Investigative Site Goerlitz
Germany Novartis Investigative Site Haag
Germany Novartis Investigative Site Halle Saale
Germany Novartis Investigative Site Hamburg
Germany Novartis Investigative Site Hamburg
Germany Novartis Investigative Site Hamburg
Germany Novartis Investigative Site Hamburg
Germany Novartis Investigative Site Hamburg
Germany Novartis Investigative Site Heidelberg
Germany Novartis Investigative Site Heilbronn
Germany Novartis Investigative Site Huy / OT Anderbeck
Germany Novartis Investigative Site Jerichow
Germany Novartis Investigative Site Kallstadt
Germany Novartis Investigative Site Kamp-Lintfort
Germany Novartis Investigative Site Kassel
Germany Novartis Investigative Site Kiel
Germany Novartis Investigative Site Koblenz
Germany Novartis Investigative Site Koeln
Germany Novartis Investigative Site Kuenzing
Germany Novartis Investigative Site Leipzig
Germany Novartis Investigative Site Leipzig
Germany Novartis Investigative Site Ludwigshafen
Germany Novartis Investigative Site Lüneburg
Germany Novartis Investigative Site Magdeburg
Germany Novartis Investigative Site Mainz
Germany Novartis Investigative Site Mainz
Germany Novartis Investigative Site Mayen
Germany Novartis Investigative Site Meissen
Germany Novartis Investigative Site Meißen
Germany Novartis Investigative Site Muehldorf Am Inn
Germany Novartis Investigative Site Muehlhausen
Germany Novartis Investigative Site Muehlheim An Der Ruhr NRW
Germany Novartis Investigative Site Neuhofen
Germany Novartis Investigative Site Neunkirchen
Germany Novartis Investigative Site Northeim
Germany Novartis Investigative Site Nurnberg
Germany Novartis Investigative Site Oelde
Germany Novartis Investigative Site Oschatz
Germany Novartis Investigative Site Paderborn
Germany Novartis Investigative Site Potsdam
Germany Novartis Investigative Site Rednitzhembach
Germany Novartis Investigative Site Reinfeld
Germany Novartis Investigative Site Rostock
Germany Novartis Investigative Site Rüdersdorf
Germany Novartis Investigative Site Siegen
Germany Novartis Investigative Site Ulm
Germany Novartis Investigative Site Wolmirstedt
Greece Novartis Investigative Site Athens GR
Greece Novartis Investigative Site Athens
Greece Novartis Investigative Site Athens
Greece Novartis Investigative Site Athens
Greece Novartis Investigative Site Chalkida
Greece Novartis Investigative Site Crete Heraklion
Greece Novartis Investigative Site Heraklion Crete
Greece Novartis Investigative Site Magoula GR
Greece Novartis Investigative Site Patras
Greece Novartis Investigative Site Thessaloniki GR
Greece Novartis Investigative Site Thessaloniki GR
Greece Novartis Investigative Site Voula GR
Guatemala Novartis Investigative Site Guatemala
Guatemala Novartis Investigative Site Guatemala City
Guatemala Novartis Investigative Site Guatemala City
Guatemala Novartis Investigative Site Guatemala City
Guatemala Novartis Investigative Site Guatemala City
Hungary Novartis Investigative Site Budapest
Hungary Novartis Investigative Site Budapest
Hungary Novartis Investigative Site Budapest
Hungary Novartis Investigative Site Budapest
Hungary Novartis Investigative Site Budapest
Hungary Novartis Investigative Site Budapest
Hungary Novartis Investigative Site Budapest
Hungary Novartis Investigative Site Csongrad
Hungary Novartis Investigative Site Debrecen
Hungary Novartis Investigative Site Gyula
Hungary Novartis Investigative Site Kistarcsa
Hungary Novartis Investigative Site Komarom
Hungary Novartis Investigative Site Miskolc
Hungary Novartis Investigative Site Mosonmagyarovar
Hungary Novartis Investigative Site Nyiregyháza
Hungary Novartis Investigative Site Pecs
Hungary Novartis Investigative Site Szeged
Hungary Novartis Investigative Site Szekesfehervar
Hungary Novartis Investigative Site Szentes
Hungary Novartis Investigative Site Zalaegerszeg Zala
Iceland Novartis Investigative Site Kopavogur
Iceland Novartis Investigative Site Reykjavik
Iceland Novartis Investigative Site Reykjavik
India Novartis Investigative Site Ahmedabad Gujarat
India Novartis Investigative Site Ahmedabad Gujarat
India Novartis Investigative Site Ahmedabad Gujarat
India Novartis Investigative Site Ahmedabad Gujarat
India Novartis Investigative Site Ahmedabad
India Novartis Investigative Site Bangalore Karnataka
India Novartis Investigative Site Bengaluru Karnataka
India Novartis Investigative Site Bikaner Rajasthan
India Novartis Investigative Site Chennai Tamil Nadu
India Novartis Investigative Site Coimbatore Tamil Nadu
India Novartis Investigative Site Coimbatore Tamilnadu
India Novartis Investigative Site Ghaziabad Uttar Pradesh
India Novartis Investigative Site Guntur Andhrapradesh
India Novartis Investigative Site Hyderabad Telangana
India Novartis Investigative Site Hyderabad Andhra Pradesh
India Novartis Investigative Site Hyderabad Andhra Pradesh
India Novartis Investigative Site Jaipur Rajasthan
India Novartis Investigative Site Jaipur Rajasthan
India Novartis Investigative Site Kochi Kerala
India Novartis Investigative Site Lucknow Uttar Pradesh
India Novartis Investigative Site Ludhiana Punjab
India Novartis Investigative Site Ludhiana Punjab
India Novartis Investigative Site Ludhiana Punjab
India Novartis Investigative Site Madurai Tamil NADU
India Novartis Investigative Site Manipal Karnataka
India Novartis Investigative Site Mohali Punjab
India Novartis Investigative Site Nagpur Maharashtra
India Novartis Investigative Site Nagpur Maharashtra
India Novartis Investigative Site Nagpur Maharashtra
India Novartis Investigative Site Nagpur Maharashtra
India Novartis Investigative Site Nampally Andhra Pradesh
India Novartis Investigative Site Nashik Maharashtra
India Novartis Investigative Site Nellore Andhra Pradesh
India Novartis Investigative Site New Delhi Delhi
India Novartis Investigative Site Pune Maharashtra
India Novartis Investigative Site Pune Maharashtra
India Novartis Investigative Site Rajasthan
India Novartis Investigative Site Secunderabad Telangana
India Novartis Investigative Site Surat Gujarat
India Novartis Investigative Site Surat Gujarat
India Novartis Investigative Site Tirupati Andhra Pradesh
India Novartis Investigative Site Vadodara Gujarat
India Novartis Investigative Site Varanasi Uttar Pradesh
India Novartis Investigative Site Vijayawada Andhra Pradesh
India Novartis Investigative Site Vijayawada Andhra Pradesh
India Novartis Investigative Site Vishakhapatnam Andhra Pradesh
Italy Novartis Investigative Site Ancona AN
Italy Novartis Investigative Site Bergamo BG
Italy Novartis Investigative Site Brescia BS
Italy Novartis Investigative Site Casorate Primo PV
Italy Novartis Investigative Site Catanzaro CZ
Italy Novartis Investigative Site Chieti CH
Italy Novartis Investigative Site Cona FE
Italy Novartis Investigative Site Cortona AR
Italy Novartis Investigative Site Fermo AP
Italy Novartis Investigative Site Firenze FI
Italy Novartis Investigative Site Foggia FG
Italy Novartis Investigative Site Massa MS
Italy Novartis Investigative Site Milano MI
Italy Novartis Investigative Site Milano MI
Italy Novartis Investigative Site Milano MI
Italy Novartis Investigative Site Monserrato CA
Italy Novartis Investigative Site Montichiari BS
Italy Novartis Investigative Site Napoli
Italy Novartis Investigative Site Novara
Italy Novartis Investigative Site Palermo PA
Italy Novartis Investigative Site Palmanova UD
Italy Novartis Investigative Site Parma PR
Italy Novartis Investigative Site Pavia PV
Italy Novartis Investigative Site Piacenza PC
Italy Novartis Investigative Site Pisa PI
Italy Novartis Investigative Site Pozzilli IS
Italy Novartis Investigative Site Roma RM
Italy Novartis Investigative Site Roma RM
Italy Novartis Investigative Site Roma RM
Italy Novartis Investigative Site Rozzano MI
Italy Novartis Investigative Site San Daniele Del Friuli UD
Italy Novartis Investigative Site Santa Maria Capua Vetere CE
Italy Novartis Investigative Site Sassari SS
Italy Novartis Investigative Site Soriano Calabro VV
Italy Novartis Investigative Site Treviglio BG
Italy Novartis Investigative Site Verona VR
Italy Novartis Investigative Site Veruno
Japan Novartis Investigative Site Amagasaki city Hyogo
Japan Novartis Investigative Site Amagasaki-city Hyogo
Japan Novartis Investigative Site Bunkyo-ku Tokyo
Japan Novartis Investigative Site Chiyoda-ku Tokyo
Japan Novartis Investigative Site Chiyoda-ku Tokyo
Japan Novartis Investigative Site Fuchu-city Tokyo
Japan Novartis Investigative Site Fujioka city Gunma
Japan Novartis Investigative Site Funabashi Chiba
Japan Novartis Investigative Site Hatsukaichi city Hiroshima
Japan Novartis Investigative Site Higashiibaraki-gun Ibaraki
Japan Novartis Investigative Site Hirakata-City Osaka
Japan Novartis Investigative Site Hitachi-city Ibaraki
Japan Novartis Investigative Site Ichinomiya Aichi
Japan Novartis Investigative Site Itabashi-ku Tokyo
Japan Novartis Investigative Site Kasuga Fukuoka
Japan Novartis Investigative Site Komatsushima-city Tokushima
Japan Novartis Investigative Site Kumamoto City Kumamoto
Japan Novartis Investigative Site Kurume-city Fukuoka
Japan Novartis Investigative Site Kusatsu-city Shiga
Japan Novartis Investigative Site Kyoto-city Kyoto
Japan Novartis Investigative Site Matsudo city Chiba
Japan Novartis Investigative Site Matsudo-city Chiba
Japan Novartis Investigative Site Nagano City Nagano
Japan Novartis Investigative Site Nagoya Aichi
Japan Novartis Investigative Site Nishinomiya Hyogo
Japan Novartis Investigative Site Ogaki-city Gifu
Japan Novartis Investigative Site Onga-gun Fukuoka
Japan Novartis Investigative Site Osaka-city Osaka
Japan Novartis Investigative Site Osaka-city Osaka
Japan Novartis Investigative Site Osaka-city Osaka
Japan Novartis Investigative Site Sakaide-city Kagawa
Japan Novartis Investigative Site Sayama-city Saitama
Japan Novartis Investigative Site Sendai city Miyagi
Japan Novartis Investigative Site Sendai-shi Miyagi
Japan Novartis Investigative Site Seto-city Aichi
Japan Novartis Investigative Site Takamatsu city Kagawa
Japan Novartis Investigative Site Takarazuka-city Hyogo
Japan Novartis Investigative Site Takasaki-city Gunma
Japan Novartis Investigative Site Takatsuki Osaka
Japan Novartis Investigative Site Tokorozawa Saitama
Japan Novartis Investigative Site Yokohama Kanagawa
Japan Novartis Investigative Site Yukuhashi Fukuoka
Korea, Republic of Novartis Investigative Site Busan
Korea, Republic of Novartis Investigative Site Busan
Korea, Republic of Novartis Investigative Site Busan
Korea, Republic of Novartis Investigative Site Daegu
Korea, Republic of Novartis Investigative Site Daegu
Korea, Republic of Novartis Investigative Site Daejeon Korea
Korea, Republic of Novartis Investigative Site Gwangju
Korea, Republic of Novartis Investigative Site Seoul
Korea, Republic of Novartis Investigative Site Seoul Korea
Korea, Republic of Novartis Investigative Site Seoul Seocho Gu
Korea, Republic of Novartis Investigative Site Suwon Gyeonggi-do
Korea, Republic of Novartis Investigative Site Uijeongbu-Si Gyeonggi-do
Korea, Republic of Novartis Investigative Site Wonju Gangwon-Do
Latvia Novartis Investigative Site Daugavpils
Latvia Novartis Investigative Site Liepaja LV
Latvia Novartis Investigative Site Riga LV
Latvia Novartis Investigative Site Riga
Latvia Novartis Investigative Site Valmiera
Latvia Novartis Investigative Site Ventspils LV
Lithuania Novartis Investigative Site Alytus
Lithuania Novartis Investigative Site Kaunas
Lithuania Novartis Investigative Site Kaunas
Lithuania Novartis Investigative Site Kaunas
Lithuania Novartis Investigative Site Kaunas LTU
Lithuania Novartis Investigative Site Kedainiai
Lithuania Novartis Investigative Site Klaipeda LTU
Lithuania Novartis Investigative Site Panevezys
Lithuania Novartis Investigative Site Siauliai
Lithuania Novartis Investigative Site Vilnius
Mexico Novartis Investigative Site Aguascalientes
Mexico Novartis Investigative Site Culiacan Sinaloa
Mexico Novartis Investigative Site Guadalajara Jalisco
Mexico Novartis Investigative Site Guadalajara Jalisco
Mexico Novartis Investigative Site Queretaro
Mexico Novartis Investigative Site San Luis Potosi
Mexico Novartis Investigative Site San Luis Potosi San Luis Potosí
Netherlands Novartis Investigative Site Alkmaar
Netherlands Novartis Investigative Site Amersfoort
Netherlands Novartis Investigative Site Amstelveen
Netherlands Novartis Investigative Site Amsterdam
Netherlands Novartis Investigative Site Amsterdam
Netherlands Novartis Investigative Site Apeldoorn DZ
Netherlands Novartis Investigative Site Breda
Netherlands Novartis Investigative Site Deventer
Netherlands Novartis Investigative Site Doetinchem
Netherlands Novartis Investigative Site Ede
Netherlands Novartis Investigative Site Gouda
Netherlands Novartis Investigative Site Groningen
Netherlands Novartis Investigative Site Haarlem
Netherlands Novartis Investigative Site Heerlen
Netherlands Novartis Investigative Site Hoorn
Netherlands Novartis Investigative Site Leeuwarden
Netherlands Novartis Investigative Site Maastricht AZ
Netherlands Novartis Investigative Site Meppel
Netherlands Novartis Investigative Site Nijmegen
Netherlands Novartis Investigative Site Rotterdam
Netherlands Novartis Investigative Site Rotterdam
Netherlands Novartis Investigative Site Sneek The Netherlands
Netherlands Novartis Investigative Site Tiel
Netherlands Novartis Investigative Site Utrecht
Netherlands Novartis Investigative Site Venlo
Norway Novartis Investigative Site Alesund
Norway Novartis Investigative Site Elverum
Norway Novartis Investigative Site Hamar
Norway Novartis Investigative Site Harstad
Norway Novartis Investigative Site Hønefoss
Norway Novartis Investigative Site Lillehammer
Norway Novartis Investigative Site Moss
Norway Novartis Investigative Site Nesttun
Norway Novartis Investigative Site Oslo
Norway Novartis Investigative Site Oslo
Norway Novartis Investigative Site Sandefjord
Norway Novartis Investigative Site Skedsmokorset
Norway Novartis Investigative Site Stavanger
Norway Novartis Investigative Site Tonsberg
Norway Novartis Investigative Site Trondheim
Norway Novartis Investigative Site Tynset
Peru Novartis Investigative Site Bellavista Lima
Peru Novartis Investigative Site Lima
Peru Novartis Investigative Site San Isidro Lima
Peru Novartis Investigative Site San Martin de Porres Lima
Poland Novartis Investigative Site Gdansk
Poland Novartis Investigative Site Gdynia
Poland Novartis Investigative Site Gdynia
Poland Novartis Investigative Site Gdynia
Poland Novartis Investigative Site Lublin
Poland Novartis Investigative Site Olawa
Poland Novartis Investigative Site Ostrow Wielkopolski
Poland Novartis Investigative Site Poznan
Poland Novartis Investigative Site Poznan
Poland Novartis Investigative Site Pulawy
Poland Novartis Investigative Site Rumia
Poland Novartis Investigative Site Skierniewice
Poland Novartis Investigative Site Torun
Poland Novartis Investigative Site Warszawa
Poland Novartis Investigative Site Wegrow
Poland Novartis Investigative Site Wloclawek
Puerto Rico Novartis Investigative Site Manati
Puerto Rico Novartis Investigative Site Mayaguez
Puerto Rico Novartis Investigative Site Ponce
Puerto Rico Novartis Investigative Site Ponce
Puerto Rico Novartis Investigative Site San Juan
Puerto Rico Novartis Investigative Site San Juan
Puerto Rico Novartis Investigative Site San Juan
Romania Novartis Investigative Site Baia Mare
Romania Novartis Investigative Site Braila ROM
Romania Novartis Investigative Site Brasov
Romania Novartis Investigative Site Bucharest
Romania Novartis Investigative Site Bucharest District 1
Romania Novartis Investigative Site Bucharest District 2
Romania Novartis Investigative Site Bucuresti District 4
Romania Novartis Investigative Site Bucuresti District 1
Romania Novartis Investigative Site Bucuresti
Romania Novartis Investigative Site Bucuresti
Romania Novartis Investigative Site Cluj Napoca
Romania Novartis Investigative Site Cluj Napoca Jud Cluj
Romania Novartis Investigative Site Cluj-Napoca
Romania Novartis Investigative Site Constanta Jud. Constanta
Romania Novartis Investigative Site Craiova Jud. Dolj
Romania Novartis Investigative Site Craiova
Romania Novartis Investigative Site Iasi Jud. Iasi
Romania Novartis Investigative Site Iasi Jud Iasi
Romania Novartis Investigative Site Oradea Jud Bihor
Romania Novartis Investigative Site Oradea
Romania Novartis Investigative Site Pitesti
Romania Novartis Investigative Site Pitesti Arges
Romania Novartis Investigative Site Sibiu
Romania Novartis Investigative Site Targu Mures
Romania Novartis Investigative Site Targu Mures
Romania Novartis Investigative Site Targu Mures Jud Mures
Romania Novartis Investigative Site Targu Mures Mures
Romania Novartis Investigative Site Targu-Mures
Romania Novartis Investigative Site Tg Mures Mures
Romania Novartis Investigative Site Timisoara Timis
Romania Novartis Investigative Site Timisoara
Romania Novartis Investigative Site Timisoara
Russian Federation Novartis Investigative Site Chelyabinsk
Russian Federation Novartis Investigative Site Chelyabinsk
Russian Federation Novartis Investigative Site Chelyabinsk
Russian Federation Novartis Investigative Site Ekaterinburg
Russian Federation Novartis Investigative Site Ekaterinburg
Russian Federation Novartis Investigative Site Ekaterinburg
Russian Federation Novartis Investigative Site Izhevsk
Russian Federation Novartis Investigative Site Kazan
Russian Federation Novartis Investigative Site Kemerovo
Russian Federation Novartis Investigative Site Kirov
Russian Federation Novartis Investigative Site Kirov
Russian Federation Novartis Investigative Site Krasnodar
Russian Federation Novartis Investigative Site Moscow
Russian Federation Novartis Investigative Site Moscow
Russian Federation Novartis Investigative Site Moscow
Russian Federation Novartis Investigative Site Moscow
Russian Federation Novartis Investigative Site Moscow
Russian Federation Novartis Investigative Site Moscow
Russian Federation Novartis Investigative Site Moscow
Russian Federation Novartis Investigative Site Novosibirsk
Russian Federation Novartis Investigative Site Penza
Russian Federation Novartis Investigative Site Perm
Russian Federation Novartis Investigative Site Perm
Russian Federation Novartis Investigative Site Petrozavodsk
Russian Federation Novartis Investigative Site Ryazan
Russian Federation Novartis Investigative Site Saint Petersburg
Russian Federation Novartis Investigative Site Saint Petersburg
Russian Federation Novartis Investigative Site Saint Petersburg
Russian Federation Novartis Investigative Site Saint Petersburg
Russian Federation Novartis Investigative Site Saint-Petersburg
Russian Federation Novartis Investigative Site Saint-Petersburg
Russian Federation Novartis Investigative Site Samara
Russian Federation Novartis Investigative Site Samara
Russian Federation Novartis Investigative Site Saratov
Russian Federation Novartis Investigative Site Saratov
Russian Federation Novartis Investigative Site Sestroretsk
Russian Federation Novartis Investigative Site Smolensk
Russian Federation Novartis Investigative Site St-Petersburg
Russian Federation Novartis Investigative Site St-Petersburg
Russian Federation Novartis Investigative Site St. Petersburg
Russian Federation Novartis Investigative Site St.- Petersburg
Russian Federation Novartis Investigative Site St.Petersburg
Russian Federation Novartis Investigative Site Syktyvkar
Russian Federation Novartis Investigative Site Tomsk
Russian Federation Novartis Investigative Site Tyumen
Russian Federation Novartis Investigative Site Vladimir
Russian Federation Novartis Investigative Site Yaroslavl
Russian Federation Novartis Investigative Site Yekaterinburg
Serbia Novartis Investigative Site Beograd
Serbia Novartis Investigative Site Nis
Serbia Novartis Investigative Site Niska Banja
Serbia Novartis Investigative Site Sremska Kamenica
Slovakia Novartis Investigative Site Banska Bystrica
Slovakia Novartis Investigative Site Bardejov
Slovakia Novartis Investigative Site Bratislava
Slovakia Novartis Investigative Site Bratislava
Slovakia Novartis Investigative Site Bratislava
Slovakia Novartis Investigative Site Bratislava Slovak Republic
Slovakia Novartis Investigative Site Brezno Slovak Republic
Slovakia Novartis Investigative Site Dubnica nad Vahom
Slovakia Novartis Investigative Site Dunajska Streda
Slovakia Novartis Investigative Site Galanta
Slovakia Novartis Investigative Site Komarno Slovak Republic
Slovakia Novartis Investigative Site Kosice Slovak Republic
Slovakia Novartis Investigative Site Kosice
Slovakia Novartis Investigative Site Kosice
Slovakia Novartis Investigative Site Levice
Slovakia Novartis Investigative Site Lucenec
Slovakia Novartis Investigative Site Lucenec
Slovakia Novartis Investigative Site Martin
Slovakia Novartis Investigative Site Nitra
Slovakia Novartis Investigative Site Nitra
Slovakia Novartis Investigative Site Nove Zamky
Slovakia Novartis Investigative Site Nove Zamky
Slovakia Novartis Investigative Site Povazska Bystrica Slovak Republic
Slovakia Novartis Investigative Site Presov Slovak Republic
Slovakia Novartis Investigative Site Presov Slovak Republic
Slovakia Novartis Investigative Site Presov
Slovakia Novartis Investigative Site Rimavska Sobota Slovak Republic
Slovakia Novartis Investigative Site Svidnik Slovak Republic
Slovakia Novartis Investigative Site Trnava
Slovakia Novartis Investigative Site Velky Krtis Slovak Republic
Slovakia Novartis Investigative Site Zilina
Slovenia Novartis Investigative Site Celje
Slovenia Novartis Investigative Site Golnik
Slovenia Novartis Investigative Site Ljubljana
South Africa Novartis Investigative Site Alberton
South Africa Novartis Investigative Site Bloemfontein
South Africa Novartis Investigative Site Cape Town
South Africa Novartis Investigative Site Cape Town
South Africa Novartis Investigative Site Cape Town Western Cape
South Africa Novartis Investigative Site Centurion
South Africa Novartis Investigative Site Durban Kwa-Zulu Natal
South Africa Novartis Investigative Site Johannesburg
South Africa Novartis Investigative Site Kempton Park
South Africa Novartis Investigative Site Pretoria
South Africa Novartis Investigative Site Western Cape
Sweden Novartis Investigative Site Boras
Sweden Novartis Investigative Site Goteborg
Sweden Novartis Investigative Site Göteborg Vastra Gotalands Lan
Sweden Novartis Investigative Site Kristianstad
Sweden Novartis Investigative Site Luleå
Sweden Novartis Investigative Site Lund
Sweden Novartis Investigative Site Lund
Sweden Novartis Investigative Site Malmö
Sweden Novartis Investigative Site Molndal
Sweden Novartis Investigative Site Östersund
Sweden Novartis Investigative Site Skanör
Sweden Novartis Investigative Site Skelleftea
Sweden Novartis Investigative Site Stockholm
Sweden Novartis Investigative Site Stockholm
Sweden Novartis Investigative Site Uddevalla
Sweden Novartis Investigative Site Vallingby
Sweden Novartis Investigative Site Vasteras
Taiwan Novartis Investigative Site Changhua
Taiwan Novartis Investigative Site Kaohsiung
Taiwan Novartis Investigative Site Kaohsiung City
Taiwan Novartis Investigative Site Taichung Taiwan ROC
Taiwan Novartis Investigative Site Taichung
Taiwan Novartis Investigative Site Tainan
Taiwan Novartis Investigative Site Taipei
Taiwan Novartis Investigative Site Taipei
Taiwan Novartis Investigative Site Taipei
Taiwan Novartis Investigative Site Taipei
Taiwan Novartis Investigative Site Taipei Taiwan, ROC
Taiwan Novartis Investigative Site Taoyuan
Taiwan Novartis Investigative Site Yilan
Turkey Novartis Investigative Site Aydin
Turkey Novartis Investigative Site Eskisehir Meselik
Turkey Novartis Investigative Site Istanbul
Turkey Novartis Investigative Site Izmir
Turkey Novartis Investigative Site Izmir
Turkey Novartis Investigative Site Kocaeli
Turkey Novartis Investigative Site Mersin
Turkey Novartis Investigative Site Sivas
United Kingdom Novartis Investigative Site Axbridge Somerset
United Kingdom Novartis Investigative Site Barnet
United Kingdom Novartis Investigative Site Basingstoke Hampshire
United Kingdom Novartis Investigative Site Berkshire
United Kingdom Novartis Investigative Site Birmingham
United Kingdom Novartis Investigative Site Birmingham
United Kingdom Novartis Investigative Site Birmingham
United Kingdom Novartis Investigative Site Cardiff
United Kingdom Novartis Investigative Site Cardiff Wales
United Kingdom Novartis Investigative Site Cheshire
United Kingdom Novartis Investigative Site Chesterfield
United Kingdom Novartis Investigative Site Chorley
United Kingdom Novartis Investigative Site Dundee Perthshire
United Kingdom Novartis Investigative Site Exeter
United Kingdom Novartis Investigative Site Glasgow
United Kingdom Novartis Investigative Site Glasgow
United Kingdom Novartis Investigative Site Glasgow
United Kingdom Novartis Investigative Site Irvine
United Kingdom Novartis Investigative Site Leicester
United Kingdom Novartis Investigative Site Liverpool
United Kingdom Novartis Investigative Site London
United Kingdom Novartis Investigative Site Manchester
United Kingdom Novartis Investigative Site Newcastle Upon Tyne
United Kingdom Novartis Investigative Site Newport
United Kingdom Novartis Investigative Site Newport Isle Of Wight
United Kingdom Novartis Investigative Site Norwich
United Kingdom Novartis Investigative Site Nottingham
United Kingdom Novartis Investigative Site Salford Manchester
United Kingdom Novartis Investigative Site Sheffield
United Kingdom Novartis Investigative Site Taunton Somerset
United Kingdom Novartis Investigative Site Whitby North Yorkshire
United Kingdom Novartis Investigative Site Wiltshire
United Kingdom Novartis Investigative Site Worcester
United Kingdom Novartis Investigative Site York
United States Novartis Investigative Site Abington Pennsylvania
United States Novartis Investigative Site Akron Ohio
United States Novartis Investigative Site Albuquerque New Mexico
United States Novartis Investigative Site Allen Texas
United States Novartis Investigative Site Altoona Pennsylvania
United States Novartis Investigative Site Ames Iowa
United States Novartis Investigative Site Anchorage Alaska
United States Novartis Investigative Site Anderson South Carolina
United States Novartis Investigative Site Ann Arbor Michigan
United States Novartis Investigative Site Asheboro North Carolina
United States Novartis Investigative Site Athens Georgia
United States Novartis Investigative Site Athens Alabama
United States Novartis Investigative Site Augusta Georgia
United States Novartis Investigative Site Aurora Colorado
United States Novartis Investigative Site Baltimore Maryland
United States Novartis Investigative Site Bartlesville Oklahoma
United States Novartis Investigative Site Baton Rouge Louisiana
United States Novartis Investigative Site Baton Rouge Louisiana
United States Novartis Investigative Site Beaumont Texas
United States Novartis Investigative Site Beaumont Texas
United States Novartis Investigative Site Beaver Pennsylvania
United States Novartis Investigative Site Bedford Texas
United States Novartis Investigative Site Beltsville Maryland
United States Novartis Investigative Site Bend Oregon
United States Novartis Investigative Site Beverly Hills California
United States Novartis Investigative Site Binghamton New York
United States Novartis Investigative Site Birmingham Alabama
United States Novartis Investigative Site Birmingham Alabama
United States Novartis Investigative Site Birmingham Alabama
United States Novartis Investigative Site Bloomington Minnesota
United States Novartis Investigative Site Bountiful Utah
United States Novartis Investigative Site Bridgeville Pennsylvania
United States Novartis Investigative Site Brownsville Texas
United States Novartis Investigative Site Burke Virginia
United States Novartis Investigative Site Burlington Massachusetts
United States Novartis Investigative Site Camden New Jersey
United States Novartis Investigative Site Camp Hill Pennsylvania
United States Novartis Investigative Site Carmichael California
United States Novartis Investigative Site Chandler Arizona
United States Novartis Investigative Site Charlotte North Carolina
United States Novartis Investigative Site Chelsea Michigan
United States Novartis Investigative Site Chicago Illinois
United States Novartis Investigative Site Cincinnati Ohio
United States Novartis Investigative Site Cincinnati Ohio
United States Novartis Investigative Site Clearwater Florida
United States Novartis Investigative Site Cleveland Ohio
United States Novartis Investigative Site Coeur d'Alene Idaho
United States Novartis Investigative Site Colorado Springs Colorado
United States Novartis Investigative Site Columbia South Carolina
United States Novartis Investigative Site Columbia Maryland
United States Novartis Investigative Site Columbia Missouri
United States Novartis Investigative Site Columbus Ohio
United States Novartis Investigative Site Coral Springs Florida
United States Novartis Investigative Site Covington Georgia
United States Novartis Investigative Site Covington Louisiana
United States Novartis Investigative Site Cumberland Rhode Island
United States Novartis Investigative Site Cumming Georgia
United States Novartis Investigative Site Dallas Texas
United States Novartis Investigative Site Dallas Texas
United States Novartis Investigative Site Dallas Texas
United States Novartis Investigative Site Danville Virginia
United States Novartis Investigative Site Davie Florida
United States Novartis Investigative Site Dayton Ohio
United States Novartis Investigative Site Daytona Beach Florida
United States Novartis Investigative Site Decatur Georgia
United States Novartis Investigative Site Decatur Georgia
United States Novartis Investigative Site DeFuniak Springs Florida
United States Novartis Investigative Site Denver Colorado
United States Novartis Investigative Site Denver Colorado
United States Novartis Investigative Site Denver Colorado
United States Novartis Investigative Site Denver Colorado
United States Novartis Investigative Site Detroit Michigan
United States Novartis Investigative Site Doral Florida
United States Novartis Investigative Site Duluth Minnesota
United States Novartis Investigative Site Duluth Georgia
United States Novartis Investigative Site Edina Minnesota
United States Novartis Investigative Site Endwell New York
United States Novartis Investigative Site Erie Pennsylvania
United States Novartis Investigative Site Escondido California
United States Novartis Investigative Site Evansville Indiana
United States Novartis Investigative Site Evansville Indiana
United States Novartis Investigative Site Fairhope Alabama
United States Novartis Investigative Site Fall River Massachusetts
United States Novartis Investigative Site Fargo North Dakota
United States Novartis Investigative Site Fort Mill South Carolina
United States Novartis Investigative Site Freehold New Jersey
United States Novartis Investigative Site Fridley Minnesota
United States Novartis Investigative Site Fullerton California
United States Novartis Investigative Site Germantown Tennessee
United States Novartis Investigative Site Glendale Arizona
United States Novartis Investigative Site Gonzales Texas
United States Novartis Investigative Site Grand Blanc Michigan
United States Novartis Investigative Site Grand Forks North Dakota
United States Novartis Investigative Site Grand Island Nebraska
United States Novartis Investigative Site Greensboro North Carolina
United States Novartis Investigative Site Greensboro North Carolina
United States Novartis Investigative Site Greenville North Carolina
United States Novartis Investigative Site Greenville South Carolina
United States Novartis Investigative Site Greenville Texas
United States Novartis Investigative Site Greenville Tennessee
United States Novartis Investigative Site Greer South Carolina
United States Novartis Investigative Site Hattiesburg Mississippi
United States Novartis Investigative Site Haverhill Massachusetts
United States Novartis Investigative Site Hershey Pennsylvania
United States Novartis Investigative Site Hialeah Florida
United States Novartis Investigative Site Hickory North Carolina
United States Novartis Investigative Site Hollywood Florida
United States Novartis Investigative Site Hollywood Florida
United States Novartis Investigative Site Honolulu Hawaii
United States Novartis Investigative Site Hopewell Virginia
United States Novartis Investigative Site Hot Springs Arkansas
United States Novartis Investigative Site Houma Louisiana
United States Novartis Investigative Site Houston Texas
United States Novartis Investigative Site Houston Texas
United States Novartis Investigative Site Houston Texas
United States Novartis Investigative Site Houston Texas
United States Novartis Investigative Site Houston Texas
United States Novartis Investigative Site Houston Texas
United States Novartis Investigative Site Huntington Beach California
United States Novartis Investigative Site Huntsville Alabama
United States Novartis Investigative Site Irving Texas
United States Novartis Investigative Site Jackson Tennessee
United States Novartis Investigative Site Jackson Mississippi
United States Novartis Investigative Site Jacksonville Florida
United States Novartis Investigative Site Jacksonville Florida
United States Novartis Investigative Site Jacksonville Florida
United States Novartis Investigative Site Jacksonville Florida
United States Novartis Investigative Site Jacksonville Beach Florida
United States Novartis Investigative Site Jerseyville Illinois
United States Novartis Investigative Site Johnson City Tennessee
United States Novartis Investigative Site Jonesboro Arkansas
United States Novartis Investigative Site Jupiter Florida
United States Novartis Investigative Site Kalamazoo Michigan
United States Novartis Investigative Site Kansas City Kansas
United States Novartis Investigative Site Kansas City Missouri
United States Novartis Investigative Site Kew Gardens New York
United States Novartis Investigative Site Knoxville Tennessee
United States Novartis Investigative Site Knoxville Tennessee
United States Novartis Investigative Site Knoxville Tennessee
United States Novartis Investigative Site Lafayette Louisiana
United States Novartis Investigative Site Lafayette Louisiana
United States Novartis Investigative Site Lake Jackson Texas
United States Novartis Investigative Site Lancaster California
United States Novartis Investigative Site Las Vegas Nevada
United States Novartis Investigative Site Layton Utah
United States Novartis Investigative Site Leander Texas
United States Novartis Investigative Site Lexington Kentucky
United States Novartis Investigative Site Lincoln Nebraska
United States Novartis Investigative Site Little Rock Arkansas
United States Novartis Investigative Site Livingston Texas
United States Novartis Investigative Site Lodi New Jersey
United States Novartis Investigative Site Loma Linda California
United States Novartis Investigative Site Loma Linda California
United States Novartis Investigative Site Lombard Illinois
United States Novartis Investigative Site Long Beach California
United States Novartis Investigative Site Los Angeles California
United States Novartis Investigative Site Los Angeles California
United States Novartis Investigative Site Los Gatos California
United States Novartis Investigative Site Louisville Kentucky
United States Novartis Investigative Site Lufkin Texas
United States Novartis Investigative Site Macon Georgia
United States Novartis Investigative Site Madison Wisconsin
United States Novartis Investigative Site Madisonville Kentucky
United States Novartis Investigative Site Mandeville Louisiana
United States Novartis Investigative Site Marion Ohio
United States Novartis Investigative Site Marshall Texas
United States Novartis Investigative Site McAllen Texas
United States Novartis Investigative Site McKinney Texas
United States Novartis Investigative Site Melrose Park Illinois
United States Novartis Investigative Site Memphis Tennessee
United States Novartis Investigative Site Metairie Louisiana
United States Novartis Investigative Site Metairie Louisiana
United States Novartis Investigative Site Miami Florida
United States Novartis Investigative Site Miami Florida
United States Novartis Investigative Site Miami Florida
United States Novartis Investigative Site Miami Florida
United States Novartis Investigative Site Miami Beach Florida
United States Novartis Investigative Site Midland Michigan
United States Novartis Investigative Site Minden Louisiana
United States Novartis Investigative Site Mineola New York
United States Novartis Investigative Site Minneapolis Minnesota
United States Novartis Investigative Site Mission Viejo California
* Note: There are 1133 locations in all - only the first 1000 are shown.

Sponsors (1)

Lead Sponsor Collaborator
Novartis Pharmaceuticals

Countries where clinical trial is conducted

United States,  Argentina,  Australia,  Austria,  Belgium,  Brazil,  Bulgaria,  Canada,  China,  Colombia,  Croatia,  Czechia,  Estonia,  Germany,  Greece,  Guatemala,  Hungary,  Iceland,  India,  Italy,  Japan,  Korea, Republic of,  Latvia,  Lithuania,  Mexico,  Netherlands,  Norway,  Peru,  Poland,  Puerto Rico,  Romania,  Russian Federation,  Serbia,  Slovakia,  Slovenia,  South Africa,  Sweden,  Taiwan,  Turkey,  United Kingdom, 

Outcome

Type Measure Description Time frame Safety issue
Primary Analysis of Core Phase First CEC Confirmed Major Adverse Cardiovascular Events (MACE) and Its Components Time to occurrence of CEC (Cardiovascular clinical events adjudication committee) confirmed MACE, which was a composite endpoint consisting of CEC confirmed CV death, CEC confirmed non-fatal MI,or CEC confirmed non-fatal stroke. Patients with the CEC adjudicated reason for death of "Unknown" were counted as CV (cardiovascular) death. From randomization, to end of treatment plus 30 days, up to approximately 6 years
Primary Substudy 1 (Core Phase): Change From Baseline in Carotid Plaque Burden in the Bifurcation Region of the Index Carotid Artery 24 months
Primary Substudy 2 (Core Phase): Change From Baseline of the Insulin Secretion Rate (ISR) Relative to Glucose 0-30 Min Defined as F30 = AUCISR 0-30 / AUCGluc 0-30 Averaged Across the Year 3, 4, 5 Visits From randomization up to approximately 6 years
Secondary Patients With Core Phase CEC Confirmed CV Death, Non-fatal MI, Non-fatal Stroke, or Hospitalization for Unstable Angina Requiring Unplanned Revascularization Occurrence of the composite cardiovascular endpoint consisting of cardiovascular death, non-fatal MI, non-fatal stroke or hospitalization for unstable angina requiring unplanned revascularization.
MACE includes CV death, non-fatal MI and non-fatal stroke. CEC = Clinical Endpoints Committee
From randomization, to end of treatment pus 30 days, up to approximately 6 years
Secondary Patients With Core Phase New Onset Type 2 Diabetes Among Patients With Pre-diabetes at Randomization Time to CEC confirmed new onset of type 2 diabetes among those with pre-diabetes at randomization (i.e. excluding those that are normoglycemic at baseline) From randomization up to approximately 6 years
Secondary Core Phase All-cause Mortality, Non-fatal MI, or Non-fatal Stroke Occurrence of the composite endpoint consisting of all-cause mortality, non-fatal IM, or non-fatal stroke From randomization, to end of treatment plus 30 days, up to approximately 6 years
Secondary Core Phase All-cause Mortality Number of participant deaths From randomization, to end of treatment plus 30 days, up to approximately 6 years
Secondary Summary of Adverse Events (Core Phase) Summary of Adverse Events (AEs) and Serious Adverse Events (SAEs) occurring during the double-blind Core phase of the study. AEs/SAEs are any signs or symptoms that occur during the study treatment. From randomization, to end of treatment plus 30 days, up to approximately 6 years
Secondary Summary of Adverse Events (Extension Phase) Summary of Adverse Events (AEs) and Serious Adverse Events (SAEs) occurring during the Extension phase of the study. AEs/SAEs are any signs or symptoms that occur during the study treatment. From start of Extension phase, to end of treatment plus 30 days, up to approximately 2 years
Secondary Substudy 1 (Core Phase): Change From Baseline of the Total Vessel Wall Area at Month 3 in the Bifurcation Region of the Index Carotid Artery 3 months
Secondary Substudy 1 (Core Phase): Mean Total Vessel Wall Area Across the Left and Right Carotid Artery at Month 3 and Month 24 24 months
Secondary Substudy 1 (Core Phase): Change From Baseline in Corresponding Total Vessel Wall Area in the Left and Right Carotid Arteries 24 months
Secondary Substudy 1 (Core Phase): The Existence of a Baseline Total Vessel Wall Area by Treatment Interaction as Well as the Consistency of the Treatment Effect Across Subgroups 24 months
Secondary Substudy 2 (Core Phase): Change From Baseline in Insulin Sensitivity Index From randomization up to approximately 6 years
Secondary Substudy 2 (Core Phase): Change From Baseline in OGTT Stimulated Area Under Curve (AUC) 0-120 Min of Glucose Concentration, Insulin Concentration, Pro-insulin Concentration, and Insulin Concentration/Glucose Concentration Ratio From randomization up to approximately 6 years
Secondary Substudy 2 (Core Phase): Change From Baseline in Fasting Pro-Insulin Concentration/Insulin Concentration Ratio From randomization up to approximately 6 years
Secondary Substudy 2 (Core Phase): Change From Baseline in OGTT Stimulated Area Under the Curve (AUC) 0-120 Min of C-peptide Concentration From randomization up to approximately 6 years
See also
  Status Clinical Trial Phase
Recruiting NCT05052918 - The Effect of Exercise and Metformin on Carotid Intima-media Thickness in Patients With Prediabetes N/A
Recruiting NCT04511234 - Sirolimus Coated Balloon Versus Standard Balloon for SFA and Popliteal Artery Disease N/A
Completed NCT05906797 - Impact of Non-surgical Periodontal Therapy in the Improvement of Early Endothelial Dysfunction in Subjects With Periodontitis. N/A
Completed NCT03273972 - INvestigating the Lowest Threshold of Vascular bENefits From LDL Lowering With a PCSK9 InhibiTor in healthY Volunteers N/A
Suspended NCT02932176 - Machine Learning for Handheld Vascular Studies
Recruiting NCT05158257 - Clinical Of Plain Balloon Dilatation Combined Stent Versus Endovascular Debulking Combined Drug-coated Balloon to Treat Arteriosclerosis Occlusive Disease of Lower Extremity N/A
Completed NCT01212900 - Randomized Trial of Imaging Versus Risk Factor-Based Therapy for Plaque Regression Phase 4
Completed NCT03697382 - Effect of Daily Steps on Fat Metabolism N/A
Recruiting NCT06230406 - T-Mem GEne in Atherosclerosis
Completed NCT03654313 - Single and Multiple Ascending Doses of MEDI6570 in Subjects With Type 2 Diabetes Mellitus Phase 1
Completed NCT00382564 - Magnetic Resonance Angiography to Diagnose Atherosclerotic Disease N/A
Recruiting NCT02894931 - Effects of Dietary Interventions on Serum and Macrophage Atherogenicity N/A
Completed NCT02998918 - Effects of Short-term Curcumin and Multi-polyphenol Supplementation on the Anti-inflammatory Properties of HDL N/A
Not yet recruiting NCT02578355 - National Plaque Registry and Database N/A
Recruiting NCT02265250 - Pilot Study-Magnetic Resonance Imaging for Global Atherosclerosis Risk Assessment
Completed NCT02268513 - Mediators of Atherosclerosis in South Asians Living in America (MASALA) Social Network Study
Completed NCT02224339 - New Technologies to Determine Carotid Plaque Vulnerability
Completed NCT03393377 - Preventive Arterial Wall Phenotype and Low-dose Fluvastatin/Valsartan Combination N/A
Completed NCT02116829 - Is There Room for Butter in a Healthy Diet? N/A
Completed NCT02377310 - Pd/Pa vs iFRâ„¢ in an Unselected Population Referred for Invasive Angiography N/A